A股異動丨依米康漲停 子公司桑瑞思應急承建核酸檢測室
格隆匯3月2日丨依米康(300249.SZ)漲停,報6.95元,總市值30.4億元。依米康全資子公司桑瑞思於2月14日下午接到河北省高碑店市應對新型冠狀病毒感染的肺炎疫情工作領導小組辦公室緊急邀請函,需在5天內全力搶建高碑店市醫院抗擊新冠肺炎疫情核酸檢測PCR實驗室。桑瑞思將在5天內交付一座高效率、高品質的“核酸檢測實驗室”,為高碑店市控制疫情傳播提供有力的檢測技術支撐。據瞭解,疫情期間,桑瑞思為各醫院提供“醫院負壓隔離病房”、“發熱門診”等設施的整體諮詢、解決方案和應急建設服務,截至目前已陸續承建完成宿州市第三人民醫院續建項目醫療氣體工程、天津市津南區鹹水沽醫院遷址擴建項目交付工作,另四川大學華西醫院空港醫院負壓病房等眾多項目也正在緊鑼密鼓籌備中,助力疫情防控。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.